Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma.

Objective: To evaluate the efficacy of low dose apatinib plus chemotherapy on advanced gastric carcinoma.

Methods: Eligible 50 patients with advanced gastric carcinoma admitted to the hospital from January 2019 to March 2020 were enrolled, and they were assigned into the control group ( = 25, chemotherapy) and observation group (apatinib plus chemotherapy). Changes of CEA, CA72-4, and VEGF levels were measured, and the efficacy of the two groups was evaluated by referring to KPS and RECIST.

Results: Significant reduction was observed in CEA, CA72-4, and VEGF in both groups, and the treatment in the observation group resulted in a greater reduction (all < 0.05). The observation group obtained significantly higher KPS scores of compared with the control group ( < 0.05). In addition, the treatment in the observation group led to a better control rate in relative to the control group according to RECIST the score ( < 0.05).

Conclusion: The combination of low dose apatinib and chemotherapy might be a promising option for advanced gastric cancer and it merits clinical application.